This continuing medical education (CME) activity will provide highlights from 2 Live Grand Round Sessions, offering expert insights on key concepts in immunotherapy for advanced NSCLC. Core topics include the rationale for immunotherapy, the critical importance of guideline-driven biomarker testing in patient selection, and the most current data on checkpoint inhibitor monotherapies, combinations, and emerging regimens.
Completion of the course will help you:
Identify patients with advanced NSCLC eligible for frontline immunotherapy using biomarker test results
Apply efficacy and safety data on frontline immunotherapy when treating patients with advanced NSCLC
This activity is intended for oncology, pathology, and pulmonology clinicians (MD/DO/NP/PA) engaged in the care of patients with non-small cell lung cancer (NSCLC).